Evaluation of IFNα bioavailability by MxA mRNA in HCV patients
- 1 April 2002
- journal article
- research article
- Published by Elsevier in Journal of Immunological Methods
- Vol. 262 (1-2) , 187-190
- https://doi.org/10.1016/s0022-1759(02)00008-x
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Evaluation of bioavailability of three types of IFNβ in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantificationJournal of Immunological Methods, 2001
- Phase I Trial of 40-kd Branched Pegylated Interferon Alfa-2a for Patients With Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2001
- MxA gene expression in peripheral blood mononuclear cells from patients infected chronically with hepatitis C virus treated with interferon-?Journal of Medical Virology, 2000
- Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodiesNeurology, 1999
- Correlation of Interferon-Induced Expression of MxA mRNA in Peripheral Blood Mononuclear Cells with the Response of Patients with Chronic Active Hepatitis C to IFN-alpha TherapyJournal of Interferon & Cytokine Research, 1999
- Ribavirin and interferon alfa‐2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactionsBritish Journal of Clinical Pharmacology, 1998
- The MxA protein levels in whole blood lysates of patients with various viral infectionsJournal of Virological Methods, 1998
- Strong transient expression of the type I interferon-induced MxA protein in hepatitis A but not in acute hepatitis B and CHepatology, 1994